Acrivon Therapeutics, Inc. Common Stock
NASDAQ:ACRVBiotechnology
+$0.05 today
- Market cap
- $66.94M
- Beta
- 1.91
- P/E (TTM)
- -0.8
- EPS (TTM)
- -$2.00
Volume 0.61M
Average 0.60M
ACRV Short-term Investments
Marketable securities and deposits the company expects to convert to cash within a year.
Acrivon Therapeutics, Inc. Common StockNASDAQ: ACRV
Short-term Investments · Q1 FY2026 · quarter ended Mar 2026
Short-term investments falls 42.4% from a year ago
Short-term investments stood at $63.67M at the end of Q1 FY2026, down 42.4% from a year earlier and down 17.4% from the prior quarter. Over 3 fiscal years it compounded at -7.8% a year.
Context
- Short-term investments amounted to 59.0% of total assets at the end of Q1 FY2026, down 3.6 pp from a year earlier.
- Short-term investments increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether short-term investments keeps falling in the next quarterly balance sheet after a -42.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Short-term Investments history
USD · from the balance sheet
- Latest · FY2025
- 77.08M USD
- Year-over-year change
- -44.8%
| Period | Period end | Short-term Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 77.08M | -44.8% |
| FY2024 | 2024-12-31 | 139.66M | +52.7% |
| FY2023 | 2023-12-31 | 91.44M | -6.9% |
| FY2022 | 2022-12-31 | 98.23M | — |
| FY2021 | 2021-12-31 | 0 | — |
Short-term Investments vs competitors
How ACRV compares with its peers on the latest reported figures
- ACRV's Mar 2026 short-term investments of $63.67M is the 2nd highest of the 10 companies compared; the peer median is $10.28M.
- Its year-over-year change of -42.4% is the 4th highest of 6, against a peer median of -22.4%.
- Short-term investments amounts to 59.0% of total assets for ACRV, versus a peer median of 5.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $224.19M | +765.2% | -14.4% | 95.3% | |
ACRVAcrivon Therapeutics, Inc. Common Stock | Mar 2026 | $63.67M | -42.4% | -7.8% | 59.0% |
| Mar 2026 | $56.51M | -14.4% | +6.6% | 70.9% | |
| Mar 2026 | $54.42M | -50.1% | -17.3% | 56.4% | |
| Mar 2026 | $17.22M | — | — | 26.7% | |
| Mar 2026 | $10.28M | -22.4% | -41.4% | 5.7% | |
| Mar 2026 | $0 | — | — | 0.0% | |
CBUSCibus, Inc. | Mar 2026 | $0 | — | — | 0.0% |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | -100.0% | — | 0.0% | |
| Peer median (excluding ACRV) | $10.28M | -22.4% | -15.9% | 5.7% | |
Competitors are the stored peer set for ACRV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 99.6M | 29.52M | 36.02M | 39.82M | 41.5M |
| Short-term Investments | 0 | 98.23M | 91.44M | 139.66M | 77.08M |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 4.34M | 2.23M | 2.15M | 1.86M |
| Total Current Assets | 100.41M | 132.1M | 129.69M | 181.63M | 120.45M |
| Property, Plant & Equipment (Net) | 5.79M | 6.86M | 7.91M | 8.03M | 7.42M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 41.88M | 0 | 5.09M | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 388K | 388K | 665K | 1.85M | 1.86M |
| Total Non-current Assets | 6.18M | 49.13M | 8.57M | 14.96M | 9.27M |
| Total Assets | 106.59M | 181.23M | 138.27M | 196.59M | 129.72M |
| Account Payables | 964K | 904K | 5.05M | 758K | 2.28M |
| Short-term Debt | 0 | 0 | 0 | 1.06M | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 66K | 69K | 0 | 0 | 0 |
| Other Current Liabilities | 667K | 2.66M | 3.86M | 5.46M | 5.56M |
| Total Current Liabilities | 2.91M | 6.52M | 13.3M | 17.21M | 15.66M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 122.52M | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 127.48M | 4.24M | 3.77M | 2.59M | 1.54M |
| Total Liabilities | 130.4M | 10.75M | 17.07M | 19.8M | 17.2M |
| Common Stock | 2K | 22K | 23K | 31K | 31K |
| Retained Earnings | (24.87M) | (56.03M) | (116.42M) | (196.98M) | (274.88M) |
| Accumulated OCI | 0 | (95K) | (83K) | 447K | 111K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | (23.81M) | 170.48M | 121.2M | 176.79M | 112.52M |
| Total Debt | 5.63M | 4.96M | 4.64M | 3.65M | 2.71M |
| Net Debt | (93.98M) | (24.56M) | (31.37M) | (36.17M) | (38.79M) |
Acrivon Therapeutics, Inc. Common Stock
NASDAQ:ACRV
Intrinsic Alpha fair value
Locked
Current Price
$1.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.